Ono Pharmaceutical Co., Ltd. (OPHLY)
Key Executives
| Name | Title | Pay | Exercised | Year Born |
|---|---|---|---|---|
| Mr. Gyo Sagara | CEO & Chairman of the Board | 983.63k | -- | 1958 |
| Mr. Toichi Takino Ph.D. | President, COO & Representative Director | -- | -- | 1968 |
| Mr. Masaki Ito | Corp. Offcr. and Div. Dir. of Corp. Strategy & Planning, Bus. Mgmt., and Corp. Tax | -- | -- | -- |
| Takehiro Yamada | Corporate Officer & Head of Risk and Compliance Management Department | -- | -- | -- |
| Masayuki Tanigawa | Corporate Officer & Head of Business Strategy Headquarters | -- | -- | -- |
| Hiromu Habashita Ph.D. | Corporate Officer & Deputy Executive Director, Discovery & Research | -- | -- | -- |
| Shinji Takai M.D., Ph.D. | Corporate Officer & Head of Medical Affairs | -- | -- | -- |
| Satoshi Takahagi | Senior Director of EHS Promotion & Corporate Executive Officer | -- | -- | -- |
| Akira Takada | Corporate Executive Officer &Exe. Dir. of CMC & Production | -- | -- | -- |
| Mr. Tatsuya Okamoto | Head of Development Div., Oncology Clinical Development Div. & Global Development Management Unit | -- | -- | -- |
Ono Pharmaceutical Co., Ltd.
- Sector:
- Healthcare
- Industry: Drug Manufacturers - General
Description
Ono Pharmaceutical Co., Ltd., together with its subsidiaries, produces, purchases, and sells pharmaceuticals and diagnostic reagents worldwide. It offers Opdivo Intravenous Infusion and Kyprolis Intravenous Injection for malignant tumors; Emend capsules/Proemend intravenous injections for chemotherapy-induced nausea and vomiting; Demser capsules for the symptoms in patients with pheochromocytoma; and Mektovi, Velexbru, and Braftovi capsules for malignant tumors, as well as ADLUMIZ tablets for cancer cachexia. The company also provides Glactiv tablets for type 2 diabetes; Forxiga tablets for diabetes; Onoact Intravenous Infusion for tachyarrhythmia; Opalmon tablets to treat peripheral circulatory disorder; Coralan for chronic heart failure; Orencia injections for rheumatoid arthritis; Rivastach patches for Alzheimer's disease; Ongentys tablets for Parkinson's disease; Parsabiv, an intravenous infusion for dialysis patients; Staybla tablets for overactive bladder; Onon capsules and Dry Syrups for bronchial asthma and allergic rhinitis; and JOYCLU intra-articular injection for the improvement of joint function, as well as Recalbon tablets for osteoporosis. In addition, it develops products for hepatocellular and urothelial carcinoma; ovarian, bladder, prostate, pancreatic, gastric, esophageal, colorectal, thyroid, cell lung, and breast cancer; acute myeloid leukemia; solid tumors; myelodysplastic syndrome; melanoma; T-cell lymphoma; tachyarrhythmia; pemphigus; scleroderma; seizures; diabetic polyneuropathy; neurodegenerative diseases; autoimmune diseases; narcolepsy; and thrombosis. The company has a collaboration with Adimab, LLC to discover novel antibody drugs; a research collaboration with Turbine Ltd. to identify and validate novel oncology targets; Harvard University for validating novel therapeutic targets; and a strategic drug discovery collaboration with Sibylla Biotech in central nervous system disorders. The company was founded in 1717 and is headquartered in Osaka, Japan.
Corporate Governance
Upcoming Events
July 29, 2025 at 3:00 AM UTC - August 4, 2025 at 3:00 AM UTC
Ono Pharmaceutical Co., Ltd. Earnings Date
Recent Events
September 30, 2024 at 12:00 AM UTC
Ex-Dividend Date
December 16, 2020 at 12:00 AM UTC
Dividend Date